Seelos Therapeutics Inc. (SEEL) Financial Statements (2024 and earlier)

Company Profile

Business Address 300 PARK AVENUE
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,99615,53378,73415,66210,2613,579
Cash and cash equivalents2,99615,53378,73415,66210,2613,579
Receivables763     
Prepaid expense128304246   
Other undisclosed current assets1,5166,8374,4811,832835106
Total current assets:5,40322,67483,46117,49411,0963,685
Noncurrent Assets
Operating lease, right-of-use asset157239  
Property, plant and equipment      38
Other noncurrent assets      37
Total noncurrent assets:157239  75
TOTAL ASSETS:5,41822,74683,50017,49411,0963,760
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,91910,9085,4213,8112,7151,151
Employee-related liabilities   272
Accounts payable16,4033,6261,6931,887796235
Accrued liabilities2,5167,2823,7281,9241,919644
Debt14,21311,8651,0302,431  
Derivative instruments and hedges, liabilities   4241,062963 
Disposal group, including discontinued operation      21
Other undisclosed current liabilities5,7962,3851,4121257,100 
Total current liabilities:38,92825,1588,2877,42910,7781,172
Noncurrent Liabilities
Long-term debt and lease obligation  8,18417,8907,293  
Long-term debt, excluding current maturities  8,18417,8907,293  
Liabilities, other than long-term debt  15   16
Other liabilities      16
Operating lease, liability  15   
Other undisclosed noncurrent liabilities    200325 
Total noncurrent liabilities:  8,19917,8907,49332516
Total liabilities:38,92833,35726,17714,92211,1031,188
Equity
Equity, attributable to parent, including:(33,510)(10,611)57,3232,572(7)2,572
Common stock10107105542728
Additional paid in capital219,106204,026198,42877,68056,027327,773
Retained earnings (accumulated deficit)(252,626)(214,744)141,210(75,162)(56,061)(325,229)
Other undisclosed equity, attributable to parent   (282,420)   
Total equity:(33,510)(10,611)57,3232,572(7)2,572
TOTAL LIABILITIES AND EQUITY:5,41822,74683,50017,49411,0963,760

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues2,20312111345375 
Net investment income19812111345151 
Gross profit:2,20312111345375 
Operating expenses(42,702)(70,916)(61,669)(18,759)(30,122)(9,148)
Other undisclosed operating loss  (121)(113)(45)  
Operating loss:(40,499)(70,916)(61,669)(18,759)(29,747)(9,148)
Nonoperating income (expense)2,617(2,618)(4,379)(342)(21,508)(70)
Other nonoperating income (expense)17,995292(517)  1
Interest and debt expense(9,151)(14)2,387(164)(29) 
Loss from continuing operations:(47,033)(73,548)(63,661)(19,265)(51,284)(9,218)
Loss before gain (loss) on sale of properties:(63,661)(19,265)(51,284)(9,218)
Net loss:(47,033)(73,548)(63,661)(19,265)(51,284)(9,218)
Other undisclosed net income (loss) attributable to parent9,15114(2,387)16429(24)
Net loss available to common stockholders, basic:(37,882)(73,534)(66,048)(19,101)(51,255)(9,242)
Other undisclosed net loss available to common stockholders, diluted      
Net loss available to common stockholders, diluted:(37,882)(73,534)(66,048)(19,101)(51,255)(9,242)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(47,033)(73,548)(63,661)(19,265)(51,284)(9,218)
Comprehensive loss, net of tax, attributable to parent:(47,033)(73,548)(63,661)(19,265)(51,284)(9,218)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: